The Compatible of Chlorhexidine and Toothpaste Formulations in Single-use Oral Care Sets Enhance an Effectiveness on Ventilator-Associated Pneumonia Prevention

AUTHORS

Chalermpong Saenjum^{1,2}, Thanawat Pattananandecha^{1,2,3}, Sutasinee Apichai^{1,2,3}, Teerapat Ouirungroj^{2,3,4}, Phisit Uirungroj^{3,4}, Akeau Unahalekhaka⁵

THE HAI UNIVERSITY OF NURSING

AFFILIATIONS

¹ Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand

- ² Research Center for Innovation in Analytical Science and Technology for Biodiversity based Economic and Society (I-ANALY-S-T_B.BES-CMU), Multidisciplinary Research Institute (MDRI), Chiang Mai University, Chiang Mai, Thailand
- ³ Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand
- ⁴ PoseHealthCare Ltd., 1 Soi Ramintra 107, Ramintra Rd., Kannayao, Bangkok, Thailand
- ⁵ Department of Public Health Nursing, Faculty of Nursing, Chiang Mai University, Chiang Mai, Thailand

RES-376



INTRODUCTION

Chlorhexidine gluconate (CHG) is a cationic disinfectant. The positive charge of CHG molecules binds to phospholipids negative charge in bacterial cell walls, causing membrane disruption. CHG is widely used in oral care and infection prevention, including reducing ventilator-associated pneumonia (VAP). However, interactions with anionic or non-ionic surfactants in commercial toothpaste may reduce its effectiveness, highlighting the need for compatible formulations in standardized oral care protocols.

OBJECTIVES

Investigated in vitro kinetic incompatibilities (physical, chemical, and therapeutic) between seven commercial and two developed toothpastes mixed with 0.2% w/v chlorhexidine gluconate (CHG). The compatible formulation was selected for single-use oral care sets and then evaluate the effectiveness in reducing VAP among ICU patients.

METHODOLOGY

1. Physical Incompatibility

Tested at 1-, 5-, 10-, and 15-min exposure times.

Observed by the naked eye for visible changes.

2. Chemical Incompatibility

Determined using **High Performance Liquid Chromatography (HPLC)**.

3. Therapeutic Incompatibility

Evaluated by antibacterial activity against

- Staphylococcus aureus ATCC 25923
- Escherichia coli ATCC 25922

4. Clinical Application

The **compatible toothpaste—CHG combination** was developed into **single-use oral care sets** and used for **oral cavity cleaning** following a **standardized oral care protocol** in ICUs across **14 tertiary care hospitals**.

RESULTS

1. Physical Incompatibility




Figure 1. HPLC chromatogram of standard CHG and mixed CHG with toothpaste sample




Figure 2. Physical incompatibility of toothpaste samples exposed to CHG for (A) 1, (B) 5, (C) 10, and (D) 15 min, respectively.

io, and

RESULTS

2. Chemical Incompatibility




Figure 3. Percent reduction of CHG after 1-, 5-, 10-, and 15-min exposure to toothpastes.

3. Therapeutic Incompatibility




Figure 4. Log reduction of *S. aureus* after 5-min exposure to a mixture of CHG and toothpaste.




Figure 5. Log reduction of *E. coli* after 5-min exposure to a mixture of CHG and toothpaste.




Figure 6. Schematic of Positively Charged CHG (or Cationic Agent) Interactions with Negatively Charged Bacterial Cell Surface, Cat-CHD Co-binding, and Membrane Disruption.

4. Clinical Application

The clinical study demonstrated a significant reduction in VAP rate from 7.74 to 5.30 per 1,000 ventilator-days (31.52% reduction, p < 0.05) after implementing the single-use oral care sets.

CONCLUSION

Anionic and non-ionic surfactants in commercial toothpastes may neutralize the positive charge of CHG, reducing its antibacterial activity. The developed CHG-compatible toothpaste in single-use oral care sets, applied under a standardized protocol, effectively reduced VAP incidence in ICU patients.